Durable Remissions in CLL With Fixed-Duration ... - CLL Support
Durable Remissions in CLL With Fixed-Duration Triplet (Gazyva, Imbruvica, Venclexta) at 4 Years
You need to be a member of this community to see this post.
Read more about...
11 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL
These results, from the CLL14 study (ClinicalTrials.gov Identifier: NCT02242942), were presented at...
Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)
Measurable residual disease (MRD) refers to the presence of disease at low levels not detected...
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jan 19,...
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
Dated 1st September 2019
In a phase III trial of patients with previously untreated CLL...
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Zanubrutinib PFS (Progression Free Survival) , ORR (Overall Response Rate) Is Superior to...
Related Posts
- Venetoclax plus obinutuzumab - the first chemotherapy-free, fixed-duration first line CLL treatment approved by Health Canada
- Acalabrutinib Plus Obinutuzumab Prolongs Progression Free Survival Compared to Other Targeted Agents in Chronic Lymphocytic Leukaemia (CLL)
- Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
- GAZYVA® (Obinutuzumab) gains TGA approval for 1st line treatment of CLL in combination with Chlorambucil in Australia
- First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
